Juno Therapeutics' stock surges in market debut


Save Story
Leer en español

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

NEW YORK (AP) — Shares of cancer treatment company Juno Therapeutics Inc. jumped 46 percent in their stock market debut Friday.

Juno genetically engineers a patient's own white blood cells to find and kill cancer cells in the body. In its clinical trials, the company said the treatment showed evidence of tumors shrinking.

The Seattle-based company raised $264.5 million after selling more than 11 million shares at $24 per share. It plans to use the cash raised to continue trials and studies. The stock is listed on the Nasdaq stock market under ticker symbol "JUNO."

The stock rose $11 to close at $35, after rising as high as $39.50 earlier.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Most recent Business stories

Related topics

Business
The Associated Press

    STAY IN THE KNOW

    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast